首页> 外文OA文献 >A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

【2h】

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

机译：脂质体Irinotecan（NAL-IRI）加上5-氟尿嘧啶/白杨（5-FU / LV）和oxaliplatin（牛）的脂质体IRINOTECAN（NAL-IRI）和Oxaliplatin（牛）的阶段1/2，开放标签，剂量 - 扩展性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Z. Wainberg; P. Boland; C. Lieu; F. Dayyani; T. Macarulla; B. Zhang; B. Belanger; Y. Moore; T. Wang; F. Maxwell; A. Dean;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Irinotecan (CPT11) Plus High-dose 5-Fluorouracil (5-FU) and Leucovorin (LV) as Salvage Therapy for Metastatic Colorectal Cancer (MCRC) after Failed Oxaliplatin Plus 5-FU and LV: a Pilot Study in Taiwan. [J] . Tai CJ, Liu JH, Chen WS, Japanese journal of clinical oncology. . 2003,第3期

机译：伊立替康（CPT11）加高剂量5-氟尿嘧啶（5-FU）和白细胞素（LV）作为奥沙利铂加5-FU和LV失败后的转移性结直肠癌（MCRC）的挽救疗法：台湾的一项初步研究。
2. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. [J] . Loupakis F, Masi G, Fornaro L, Cancer chemotherapy and pharmacology. . 2010,第3期

机译：转移性胃或胃食管交界性腺癌患者顺铂加5-氟尿嘧啶/亚叶酸钙（5-FU / LV），伊立替康+ 5-FU / LV，多西他赛+ 5-FU / LV的二期研究。
3. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma [J] . Fotios Loupakis, Gianluca Masi, Lorenzo Fornaro, Cancer Chemotherapy and Pharmacology . 2010,第3期

机译：转移性胃或胃食管交界性腺癌患者顺铂加5-氟尿嘧啶/亚叶酸钙（5-FU / LV），伊立替康+ 5-FU / LV，多西他赛+ 5-FU / LV的II期临床研究
4. HIFU for Treating Patients with Advanced Recurrent / Metastatic Cancerin Pelvis: A Preliminary Clinical Study [C] . The 3rd Asian congress on hyperthermic oncology and the 9th Chineses symposium on hyperthermic oncology . 2002

机译：HIFU治疗晚期骨盆癌复发/转移性癌症的初步临床研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy [O] . L.-T. Chen, J. Siveke, A. Wang-Gillam, -1

机译：PD-023 NAPOLI-1中各亚组之间的安全性：先前在转移性胰腺癌（mPAC）中对nal-IRI（MM-398）±5-氟尿嘧啶和亚叶酸钙（5-FU / LV）与5-FU / LV进行的3期研究吉西他滨治疗

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

著录项

相似文献

相关主题

期刊订阅